Choosing appropriate patients with systemic sclerosis for treatment by autologous stem cell transplantation

Journal of Rheumatology

Volumn 24, Issue SUPPL. 48, 1997, Pages 85-88

  Clements, Philip J ^a,c   Furst, Daniel E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BENAROYA RESEARCH INSTITUTE   (United States)

^c Box 951670 ^*  (United States)

Author keywords

Autologous; Patient selection; Scleroderma; Stem cell transplant; Systemic sclerosis

Indexed keywords

ADULT; AGE; AUTOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PATIENT SELECTION; REVIEW; RISK FACTOR; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; CONFERENCE PAPER; DISEASE DURATION; HEART DISEASE; KIDNEY DISEASE; LUNG DISEASE; PRIORITY JOURNAL; SKIN MANIFESTATION; SKINFOLD; STEM CELL TRANSPLANTATION; SURVIVAL;

ADULT; AGE FACTORS; CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PATIENT SELECTION; RISK FACTORS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0030906986     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Siebold JR: Scleroderma: In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology, 5th ed. Philadelphia: Saunders, 1997:1133-62.
2. Medsger TA Jr, Steen VD: Classification, Prognosis: In: Clements PJ, Furst DE, eds. Systemic Sclerosis. Baltimore: Williams and Wilkins, 1995:51-64.
3. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al: Early undifferentiated connective tissue disease. III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993;118:602-9.
4. Silman AJ: Scleroderma - demographics and survival. J Rheumatol 1997;(suppl 48)24:58-61.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. Clements PJ, Medsger TA Jr: Skin involvement. In: Clements PJ, Furst DE, eds. Systemic Sclerosis. Baltimore: Williams and Wilkins, 1995:389-407.
7. Clements P, Lachenbruch PA, Seibold JR, et al: Ketanserin vs placebo in systemic sclerosis trial: Predictors of long term survival (abstr). Arthritis Rheum 1995;(suppl)38:S335.
8. Clements P, Lachenbruch P, Furst D, Paulus H: The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis Rheum 1993;36:1575-9.
9. Steen VD: Factors predicting the development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86.
10. Steen VD, Conte C, Owens G, Medsger TA Jr: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
11. Steen VD, Medsger TA Jr: Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin N Amer 1990;16:1-10.
12. Clements PJ, Lachenbruch PA, Furst DE, Paulus HE, Sterz MG: Cardiac score: A semiquantitative measure of cardiac involvement which improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1991;34:1371-80.
13. Steen VD, Constantino JP, Shapiro AP, Medsger TA Jr: Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7.